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ABSTRACT We report the synthesis and evaluation of a series of iodinated
celecoxib analogues as cyclooxygenase-2 (COX-2)-targeted single photon emission
computerized tomography (SPECT) imaging agents for the detection of inflammation.
The structure-activity relationship identified 5-(4-iodophenyl)-1-{4-(methylsulfonyl)-
phenyl}-3-(trifluoromethyl)-1H-pyrazole (8) as a promising compound with IC50
values of 0.05 μM against purified COX-2 and 0.03 μM against COX-2 in activated
macrophages. The arylstannane of 8 undergoes facile radio-[
123I]-iodination upon
treatment with Na
123I/NaI and chloramine T using an EtOAc/H2Ot w o - p h a s es y s t e m .
The [
123I]-8was produced in a radiochemical yield of 85% and a radiochemical purity
of 99%. In vivo SPECT imaging demonstrated that the radiotracer was taken up by
inflamedratpawswithanaverage1.7-foldenrichmentovercontralateralnoninflamed
paws. This study suggests that conversion of celecoxib into its isomeric iodo-[
123I]-
analogues is a useful approach for generating novel and efficacious agents for COX-2-
targeted SPECT imaging of inflammation.
KEYWORDS Iodine-123, celecoxib, iododestannylation, two-phase reaction, cy-
clooxygenase-2 (COX-2), in vivo SPECT imaging
P
rostaglandins are important biological mediators of
inflammation, originating from the biotransformation
of arachidonic acid catalyzed by cyclooxygenases
(COX).
1 Constitutively expressed COX-1 is found in most
normal tissues, where it modulates homeostatic functions,
such as hemostasis, vascular tone, and cyctoprotection of the
gastric mucosa.
2Inducible COX-2is expressedin inflammatory
lesions, where it modulates pain, fever, and edema, and in
proliferative lesions where it promotes growth, angiogen-
esis and enhances the metastatic potential of tumor cells.
3The
expression of COX-2 is an early event in tumorigenesis that
plays a role in tumor progression.
4 COX-2 mRNA and protein
are detectable in a significant percentage of precursor lesions
(e.g.,colonpolypsandBarrett'sesophagus)
5,6andanevenhigher
percentage of malignant tumors (e.g., colon adenocarcinoma
and esophageal adenocarcinoma).
7,8 Recent work has shown
that selective COX-2 inhibitors are useful in the treatment of
certain human cancers.
9,10 Therefore, COX-2 is an attractive
molecular target for detection of cancers by imaging with
radiolabeled COX-2 inhibitors. In fact, syntheses of
18F- and
123I-labeled COX-2 inhibitors as potential imaging agents have
been reported.
11,12 Preliminary characterization of these com-
pounds indicated that they accumulated in COX-2-expressing
macrophages,
13-15 but the in vivo uptake in tumors of mostof
the agents did not correlate to the presence of COX-2.
16 We
recently reported that COX-2-targeted fluorescent imaging
agents can be selectively delivered into inflammatory tissues
and COX-2-expressing tumors in vivo.
17 Because an enormous
amount of medicinal chemistry has been conducted to create
COX-2-specific inhibitors, there are numerous classes of poten-
tialbuildingblocksthatareavailableforthepreparationofsingle
photon emission computerized tomography (SPECT) imaging
agents for COX-2.
18,19 For the development of COX-2-targeted
SPECT imaging agents, we synthesized a series of derivatives of
celecoxib. Here, we report the synthesis, evaluation, and radio-
labeling of [
123I]-celecoxib analogues as selective COX-2 tracers
for SPECT imaging and describe the in vivo delivery of a tracer
thatselectivelyaccumulatesintheCOX-2-expressingcarrageenan-
induced rat paw model of acute inflammation.
The Claisen reaction of iodoacetophenone (A,R
1=3-I or 4-I)
withmethyltrifluoroacetateinthepresenceofsodiummethoxide
gavetheexpectedβ-diketonesB(R
1=3-I or 4-I, and R
2=CF 3)in
80-88% yield. An ultrasonication-assisted condensation of A
(R
1=3-I or 4-I) with either dimethyl- or diethyloxalate afforded
compounds B (R
1=3-I or 4-I, and R
2=CO 2Me or CO2Et) in
65-70% yield. Alternatively, the reaction of A (R
1=3-I or 4-I)
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with succinic anhydride in the presence of lithium diisopropyla-
mide (LDA) proceeded smoothly to afford B (R
1=3-I or4-I, and
R
2=C2H4CO2H)in68-72%yield.Condensationofcompounds
B(R
1=3-I or 4-I, and R
2=C 2H4CO2H) with R
3-Ph-NHNH23HCl
(R
3=SO2NH2 or SO2Me) afforded the respective pyrazole prod-
ucts, 1-10,i n7 6 -84% yield (Scheme 1). The 1,5-regioisomers
weregeneratedalmostexclusivelybycarryingoutthereactionin
the presence of the hydrochloride salt of the substituted phenyl-
hydrazine in refluxing ethanol.
18 However, when required, the
1,5-diarylpyrazoles were separated from the minor 1,3-diaryl-
pyrazole isomers by flash chromatography.
The IC50 values for inhibition of purified human COX-2 or
ovine COX-1 by test compounds were determined bya thin-
layer chromatography (TLC) assay.
20 Hematin-reconstituted
COX-2 (66 nM) or COX-1 (44 nM) in 100 mM Tris-HCl, pH
8.0, containing 500 μM phenol was treated with several con-
centrations of inhibitors (0-66 μM) at 25 Cf o r1 7m i na n d
37Cfor3minfollowedbymetabolismof
14C-arachidonicacid
(50μM)for30sat37C.Table1displaystheinvitroCOX-1and
COX-2 inhibition data. We found that the iodo-celecoxib deriv-
ative, 1, which contains an iodo group at the meta-position of
the 5-phenyl substituent, is a potent and selective COX-2
inhibitor with a COX-2 IC50 value of 0.08 μM (COX-1 IC50>
66 μM).W h e nt h eC F 3 group of 1 was replaced by a CO2Me
substituent, the COX-2 inhibitory potency was significantly
decreased (2,C O X - 2I C 50=3.8 μM). Interestingly, the para-
iodo isomer, 3, showed better potency against purified COX-2
(IC50=0.56 μM). A further increase in COX-2 potency was ob-
served when the CO2Me group of 3 w a sr e p l a c e dw i t haC O 2Et
group (4,C O X - 2I C 50=0.26 μM).R e p l a c e m e n to ft h eC O 2Me
groupof3or4withapropionicacid(R
2=C 2H4CO2H)moiety
afforded inactive compounds, 5 and 6. However, isomeric
iodinationorreplacementoftheSO2NH2groupofcompound1
with a SO2Me group increased the COX-2 inhibitory potency
andselectivityasexhibitedbycompound8(R
3=SO 2Me,COX-2
IC50=0.05 μM). Acomplete loss of poor inhibitionwas observed
when the CF3 group of 7 or 8 w a sr e p l a c e dw i t haC O 2Me group
(compounds 9 and 10).
The ability of promising compounds to inhibit COX-2 in
intact cells was assayed in the RAW264.7 murine macro-
phage-like cell line.
21 The RAW264.7 cells were treated with
lipopolysaccharide (200 ng/mL) and γ-interferon (10 U/mL)
for7htoinduceCOX-2expressionandthentreatedwithvehicle
orthetestcompoundsatseveralconcentrations.TheIC50values
for inhibition of COX-2 by compounds 1 and 8 were 0.04 and
0.03 μM, respectively (Table 1). Among these compounds, 8
showed the most potent inhibitory activity against COX-2 in
cultured inflammatory cells without inhibition of COX-1 at con-
centrations up to 5 μM. Thus, compound 8 was selected for
radio-
123I-iodination. The remaining isomeric iodo compounds
that have low to moderate COX-2 inhibitory potency and selec-
tivityinthepurifiedCOXenzymeassaywerenottestedfortheir
inhibitory activity against COX-2 enzyme in the activated intact
RAW264.7 cell line assay.
We recently reported an efficient two-phase radioiodination
method that was used in the present case to radiolabel
compound 8.
22 The aryltributylstannane 11 of the stable iodo
compound 8was generated bya palladium-catalyzed deiodos-
tannylation reaction using hexabutylditin and tetrakis-(triphe-
nylphosphine)palladium(0)inrefluxing1,4-dioxane.Theradio-
iodination of tributylstannyl derivative 11 was conducted by
Scheme 1. Synthesis of Isomeric Iodo Compounds 1-10
a
aReagents and conditions: (a) 25% NaOMe/MeOH, methyl t-butyl
ether, 25 C, 48 h, or 25% NaOMe/MeOH, ultrasound, 45 C, 16 h, or
LDA, succinic anhydride, THF, -78 C. (b) R
3-Ph-NHNH23HCl, MeOH,
reflux 16 h, or R
3-Ph-NHNH23HCl, TEA, MeOH, reflux 16 h.
Table 1. In Vitro Purified COX-1 and COX-2 and Lipopolysacca-
ride (LPS)-Activated Macrophage-Like (RAW254.7 Cell) Cellular
COX-2 Enzyme Inhibition Assay Data of Isomeric Iodo Com-
pounds 1-10
IC50(μM)
a
compd
no.
purified
COX-1
purified
COX-2
RAW
264.7
cellCOX-2
1 >4 0.08 0.04
2 >4 3.80 NT
3 >4 0.56 NT
4 >4 0.26 2.70
5 >4 >4 NT
6 >4 >4 NT
7 >4 0.32 NT
8 >4 0.05 0.03
9 >4 >4 NT
10 >4 3.00 NT
celecoxib >4 0.03 NT
aIC50 values were determined by incubating several concentrations
of inhibitors in DMSO with purified murine COX-2 (66 nM) and ovine
COX-1(44nM)for20minfollowedbytreatmentwith1-
14C-AA(50mM)
at 37 C for 30 s. Assays were run in duplicate. NT, not tested.r2010 American Chemical Society 162 DOI: 10.1021/ml100232q|ACS Med. Chem. Lett. 2011, 2, 160–164
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electrophilic
123I-iododestannylation in an EtOAc/H2Ob i n a r y -
phasesystem usingNa
123I/NaI,chloramineT,andaqueous1N
HCl (Scheme 2). The radiolabeled product was isolated by
collecting the organic layer from the two-phase system and
evaporatingthesolventunderaflowofargon.Theelectrophilic
123IspeciesisgeneratedinthewaterlayeratpH3.5andrapidly
extracted into the EtOAc layer for subsequent electrophilic aro-
matic substitution reaction. The final product stays in the EtOAc
layer,whichlacksthepolarbyproductsofthereactiontogivethe
high radiochemical yield and purity of the product. This phase
transfer technology does not require any further chromato-
graphic purification. In a typical experiment, we reacted the
precursor 11 (20 μgi n1 . 5m Lo fE t O A c ) with the radioactive
Na
123I (17.3 mCi in 500 μLo f0 . 0 1NN a O H ) in the presence of
carrier NaI (4.5 μgi n3 0 0μLo fH 2O), chloramine-T trihydrate
(8.4 μgi n3 0 0μLo fH 2O), and aqueous 1 N HCl (300 μL).A f t e r
the reaction mixturewas stirred for 5 minat room temperature,
water (1m L) followed by EtOAc (1m L) was added. Theorganic
layer was collected, washed with water, and evaporated under
argon flow to afford [
123I]-8 (product, 14.7 mCi; radiochemical
yield, 85%; and radiochemical purity, 99%). Theradiochemical
purity was determined by a radio-TLC scan. The radiotracer
[
123I]-8coelutedwithanunlabeledstandard.Thespecificactivity
of [
123I]-8was 491 Ci/mmol, which was calculated based on the
final radiotracer obtained from the organic layer of the iodina-
tionreaction ascompared with theadded carrierin thereaction
(specific activity = 0.01473 Ci/0.00003 mmol).
Theratpawmodeliswell-documentedfortheroleofCOX-
2-derived prostaglandins as a major driving force for the
acuteedemathatresultsaftercarrageenaninjectionintothe
paw.
23 One of the significant advantages of this animal
model of inflammation is the ability to image the inflamed
paw in comparison to the noninflamed contralateral footpad,
which does not express COX-2. We injected 100 μLo f1 %
carrageenan in the rear right footpad of Sprague-Dawley rats
(325-350g)andwaited3hforinflammationtodevelop.Then,
we tail vein injected [
123I]-8 dissolved in a formulation solvent
consisting of dimethyl sulfoxide (10%),e t h a n o l(40%),a n d
sterile saline (50%)( 300 μL, 600;800 μCi) into the anesthe-
tized animals. Three hours later, the rats were reanesthetized
with2%isofluraneandplacedinaBioScanNanoSPECT/CT,and
a 30 min acquisition (24 projections   60 s per projection) was
initiated. The images were reconstructed with a resolution of
170  170  184 at 0.4 mm   0.4 mm   0.4 mm. The SPECT
images were analyzed using AMIDE.
24 Compound [
123I]-8 tar-
geted the swollen footpad selectively over the contralateral
control footpad (Figure 1). The rats were sacrificed at various
time points postinjection by isoflurane overdose. The hind feet
were removed and weighed, and radioactivity associated with
each footpad was counted with a well γ-counter. Figure 2 dis-
plays the relative uptake of [
123I]-8 in the carrageenan-injected
footpad over the control footpad obtained from measurements
ofindividual footpadradioactivityafter removal at two different
time points (3a n d6h ;p = 0.005 at 3 h).T h eu p t a k eo ft h e
radiotracer in the inflamed paw was 23.5 ( 5% of the injected
dose/g and was 11.5 ( 1% in the noninflamed paw.
Scheme 2. Radiosynthesis of [
123I]-8
a
aReagents and conditions: (a) tetrakis-(Triphenylphosphine)palla-
dium(0), bis-tributyltin, 1,4-dioxane, reflux 16 h. (b) Na
123I/NaI, chlor-
amine T, EtOAc, H2O, 1 N HCl, 25 C, 4 min.
Figure 1. In vivo SPECT/CT image of a Sprague-Dawley rat foot-
pad at 3 h post tail vein administration of [
123I]-8.
Figure 2. Relative uptake of [
123I]-8 in inflamed vs noninflamed
rat footpads at 3 and 6 h postinjection of [
123I]-8.r2010 American Chemical Society 163 DOI: 10.1021/ml100232q|ACS Med. Chem. Lett. 2011, 2, 160–164
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The importance of COX-2 in the uptake of isotope into the
inflamed footpad was probed by blocking the COX-2 active site
withanexcessofunlabeled8.Weadministeredthenonradioac-
tive compound 8 a tad o s eo f5 5m g / k g(ip) at 2 h postcarra-
geenanandwaited1hforabsorptionandblockageoftheCOX-2
active site prior to dosing with [
123I]-8(∼1 mCi, tail vein).A t3h
postinjection of [
123I]-8,w ee u t h a n i z e dt h ea n i m a l s ,r e m o v e d
the hind paws, and measured the radioactivity of the individual
pawsinthewellcounter.Therewas noincreaseofradiotracerin
the inflamed footpad as compared to the noninflamed control
footpad (calculated fold increase = 1.0 ( 0.2).
In summary, isomeric iodo analogues of celecoxib were
generated and radioiodinated such that they retain the ability
of the parent celecoxib to inhibit COX-2 selectively in purified
enzyme as well as in live inflammatory cells (e.g., compound 1
or 8). A striking observation from this study is that replacement
ofthep-tolylringwithap-iodophenylring,aswellassubstitution
of the p-SO2NH2 group of celecoxib with a p-SO2Me group,
generates compounds like 1 or 8 that are highly potent and
selectiveCOX-2 inhibitors. Itislikely thatthe [
123I]-substituentin
compound 8and the Me group in celecoxib are bioisoteric. This
observation, coupled with the structural flexibility revealed in
the present study, suggests that isomeric iodinated analogues of
celecoxib are efficacious COX-2 inhibitors, and these com-
pounds can be efficiently labeled with [
123I] for use in COX-2-
targeted SPECT imaging.
SUPPORTING INFORMATION AVAILABLE Full synthetic
procedures and analytical and spectral characterization data of
thesynthesizedcompounds.Thismaterialisavailablefreeofcharge
via the Internet at http://pubs.acs.org.
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